… efficacy of AdVs harboring the cyclooxygenase-2 (Cox-2) or the … in a phase I/II study in head
and neck cancer patients, combined … within the tumor microenvironment, facilitating immune …

… In addition to cyclooxygenase-2 (COX-2) and serum … p-AKT is a biomarker for poor prognosis
in cervical cancer. Radiation … Thus, It was recommended that additional phase I/II trials are …

… The importance of tumor microenvironment in HNSCC will … Furthermore, cyclooxygenase
2 (COX-2) overexpression and … There is currently a Phase I/II study that seeks to evaluate …

… Cyclooxygenase-2 inhibition in combination with … interesting ongoing phase I/II clinical trial
that is a assessing the use of … cancer tumor microenvironment is highly complex, with various …

… Example of a p53/activin A/cyclooxygenase-2 (COX-2)-… greatly on tumor microenvironment
and cancer type (ie, FAP … been terminated despite promising phase I/II results. A pilot …

… within tumor cells is a reliable biomarker for … phase I/II clinical trial has been arranged to
investigate the effects of combining NOX-A12 and anti-PD-1/PD-L1 treatment in CRC patients …

… biomarkers and the limited sample size, mTOR inhibitor … and ribociclib are being tested
in phase I/II clinical trials. … It has been found that celecoxib could significantly inhibit the …

… The clinical utility of molecular and image-based biomarkers … β (TGFβ) and cyclooxygenase-2
(COX-2) [30,31,32,33]. The … in the formation of the tumor microenvironment mainly via their …

… A phase I/II trial of everolimus and intravesical gemcitabine in … COX-2 inhibitor celecoxib in
preventing recurrence of … in the tumor microenvironment, such as cancers have learned how …

… prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with
carcinoma of the cervix with biomarker assessment of the tumor microenvironment. Int J Radiat …